Congressional Research Service Reports - 5 Matching Results
Search Results
- Andean Regional Initiative (ARI): FY2002 Assistance for Colombia and Neighbors
- This report discusses the Andean Regional Initiative (ARI), implemented by the Bush Administration in 2001 to provide economic and counter-narcotics assistance for Colombia and regional neighbors. The report discusses the goals of the ARI, as well as related appropriations.
- Andean Regional Initiative (ARI): FY2002 Assistance for Colombia and Neighbors
- This report discusses the Andean Regional Initiative (ARI), implemented by the Bush Administration in 2001 to provide economic and counter-narcotics assistance for Colombia and regional neighbors. The report discusses the goals of the ARI, as well as related appropriations.
- Andean Regional Initiative (ARI): FY2002 Assistance for Colombia and Neighbors
- This report discusses the Andean Regional Initiative (ARI), implemented by the Bush Administration in 2001 to provide economic and counter-narcotics assistance for Colombia and regional neighbors. The report discusses the goals of the ARI, as well as related appropriations.
- Andean Regional Initiative (ARI): FY2002 Assistance for Colombia and Neighbors
- This report discusses the Andean Regional Initiative (ARI), implemented by the Bush Administration in 2001 to provide economic and counter-narcotics assistance for Colombia and regional neighbors. The report discusses the goals of the ARI, as well as related appropriations.
- The Andean Trade Preference Act: Background and Issues for Reauthorization
- On December 4, 1991, President George Bush signed into law the Andean Trade Preference Act (ATPA) to counter illicit drug production and trade in Latin America. For ten years, it has provided preferential, mostly duty-free, treatment of selected U.S. imports from Bolivia, Colombia, Ecuador, and Peru. The goal of ATPA is to encourage increased exports, thereby promoting development and providing an incentive for Andean farmers and other workers to pursue economic alternatives to the drug trade. This report discusses the ATPA, its background, and issues regarding its potential reauthorization.